Retinitis Pigmentosa Type 11 (RP11) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Retinitis Pigmentosa Type 11 (RP11) Market Outlook

Thelansis’s “Retinitis Pigmentosa Type 11 (RP11) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Retinitis Pigmentosa Type 11 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Retinitis Pigmentosa Type 11 (RP11) Overview

Inherited retinal diseases (IRDs) possess a genetic origin, rendering them favorable candidates for RNA therapeutics treatment. Retinitis pigmentosa type 11 (RP11) is an autosomal dominant IRD among these conditions. Symptoms of RP11 typically manifest in early childhood, as patients experience a gradual decline in visual function and functional vision. By age 40, many RP11 patients find themselves in a state of legal blindness. Unfortunately, effective treatments for RP11 are currently absent. RP11 is categorized as a haploinsufficiency disorder, signifying that one copy of the relevant gene (in this case, the critical gene called PRPF31) operates normally. In contrast, the other copy carries a mutation that prevents the production of a properly functioning protein. In the context of RP11, this genetic imbalance results in insufficient protein levels within the retina, ultimately culminating in retinal disease. For haploinsufficiency conditions like RP11, RNA therapeutics offer a distinctive opportunity to enhance the deficient protein's production through various mechanisms. Achieving an upregulation of the lacking protein, often aiming to match levels seen in healthy individuals, proves indispensable in addressing the progression of the disease.

• The prevalence of retinitis pigmentosa affects approximately one in 3,500 individuals, with nearly one in 10 retinitis pigmentosa patients falling into the specific subtype known as RP11.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: